9月9日，诺和诺德盘中下跌3.08%，报45.165美元/股，成交额4.01亿美元。
消息面上，诺和诺德宣布提前终止在研心血管候选药物ziltivekimab的两项III期临床试验，原因是独立委员会评估认为这两项试验不太可能产生有别于此前失败研究的结果。两项研究均针对伴有心力衰竭和炎症的患者。诺和诺德此前寄望借助ziltivekimab打开心血管疾病市场、降低对肥胖及糖尿病药物的业务依赖，本次试验终止对其心血管管线构成重要打击。不过，针对心梗后急性治疗场景的另一项ziltivekimab试验（ARTEMIS）仍将继续推进，预计2027年上半年读出结果。同日，公司公布司美格鲁肽STEP Young三期试验积极数据，但管线挫折情绪仍主导盘面。制药行业整体承压，诺华跌13.82%，礼来跌2.44%，辉瑞跌2.27%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.